These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9145842)

  • 21. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
    Wang T; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
    Ruiz J; Sierra JM; De Anta MT; Vila J
    Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.
    Ince D; Zhang X; Silver LC; Hooper DC
    Antimicrob Agents Chemother; 2003 Jan; 47(1):274-82. PubMed ID: 12499202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide.
    Couto I; Costa SS; Viveiros M; Martins M; Amaral L
    J Antimicrob Chemother; 2008 Sep; 62(3):504-13. PubMed ID: 18511413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staphylococcus aureus mutants selected by BMS-284756.
    Discotto LF; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3273-5. PubMed ID: 11600399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
    J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
    Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
    J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1345-55. PubMed ID: 8092836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.